People with a personal or family history of psychotic disorders, people with bipolar I disorder or a history of mania, people taking lithium, and people with significant cardiovascular disease are commonly treated as poor candidates for psilocybin exposure in research and clinical safety guidance, and many programs also screen carefully for pregnancy, breastfeeding and unstable psychiatric symptoms.
Psilocybin has shown promising results in several clinical settings, but it is not appropriate for every person or every health history. Safety screening exists because the psychedelic state can sharply increase fear, confusion, blood pressure and emotional intensity for a period of time. In research settings, participant selection is narrow for that reason. (
After that starting point, the practical question becomes simple. If you are thinking about a retreat, you need to know which medical and psychiatric factors can raise risk enough that a skilled operator should pause, delay, or decline participation. That is where proper intake makes a real difference.
A history of psychosis is a major warning sign
If you have schizophrenia, schizoaffective disorder, a prior psychotic episode, or a strong family history of psychosis, most careful programs will treat that as a serious reason to avoid psilocybin. Clinical trials routinely exclude people with psychotic disorders and often exclude people with a first-degree relative who has a psychotic disorder because of concern that psychedelic exposure could trigger or worsen psychotic symptoms.
This point is important even if you feel stable right now. Psilocybin can temporarily alter perception, increase suggestibility and intensify fear or confusion. For someone with a psychosis-related risk profile, that shift can carry more danger than it does for the average screened trial participant.
Bipolar disorder needs careful review
If you have bipolar disorder, especially bipolar I disorder or any past mania, a retreat should not treat that as a routine case. Safety concerns in bipolar populations include sleep disruption, anxiety and the chance of manic symptoms. Some newer studies in bipolar II depression are moving forward, but that does not remove the need for caution, and it does not make a general retreat setting appropriate for every person with bipolar history.
If you have ever had mania, hypomania, severe agitation after antidepressants, or long periods of reduced sleep with elevated energy, that history should be reviewed in detail before any retreat discussion goes further. A careful program should want that detail up front.
SSRIs and other antidepressants can complicate a retreat
If you take an SSRI or SNRI, the first thing to know is that this is not a simple yes-or-no issue. Several trials historically asked participants to stop antidepressants before psilocybin sessions, partly because SSRIs may blunt psychedelic effects through serotonin-related changes. More recent reports suggest some people can still receive psilocybin while staying on serotonergic antidepressants, but the evidence is still mixed and program rules vary.
That means you should never assume a retreat can safely sort this out with a casual email. If you are taking an SSRI, SNRI, MAOI, trazodone, mirtazapine, or another psychiatric medication, a real medication review is needed. In many cases the issue is not just safety. It is also about unpredictable intensity, weaker effects, withdrawal risk if medication is stopped too fast, and destabilization if a prescribing clinician is left out of the process.
Lithium is a high-risk combination
If you take lithium, psilocybin is widely treated as a strong contraindication. Recent clinical guidance for psychiatrists states that psilocybin is strongly contraindicated with lithium because of reported seizure and delirium risk.
That point should be treated very seriously. A retreat that brushes past lithium use is giving you a clear reason to walk away.
Severe heart conditions need real caution
If you have coronary artery disease, uncontrolled hypertension, a serious arrhythmia history, prior heart failure, a major structural heart condition, or a high stroke risk, psilocybin may not be appropriate in a retreat setting. Reviews of cardiovascular safety report that psilocybin commonly causes transient increases in heart rate and blood pressure, and more medically fragile people can face higher risk.
This is one reason serious programs ask about blood pressure, heart history and cardiac medications before acceptance. A person who is healthy enough for ordinary travel is not automatically a good candidate for a psychedelic session.
Pregnancy, breastfeeding and unstable symptoms should pause the plan
If you are pregnant or breastfeeding, psilocybin is generally avoided because safety data are limited and possible fetal or infant risks remain unclear. Reviews aimed at clinicians advise avoiding psilocybin in these situations.
If you are in an acutely unstable mental state, that should also pause the idea of a retreat. Recent severe depression with active suicidality, recent psychiatric hospitalization, active substance withdrawal, major sleep disruption, panic that is already poorly controlled, or current dissociation can all raise the stakes. A retreat should not be treated as a substitute for acute medical or psychiatric care.
Why intake calls matter so much
A good health review is more than a form. It should cover psychiatric history, family history, medications, cardiovascular history, sleep, current stability and recent changes in symptoms. The reason this matters is simple. The same dose can land very differently in two people with different risk profiles. Research guidance from the FDA stresses the need for careful selection, preparation and monitoring in psychedelic investigations.
If a retreat does not include a real one-to-one health call, it is harder to know if the operator is catching the details that can change a safe plan into an unsafe one. A live screening conversation gives space to ask about medications, past episodes, blood pressure history and red flags that do not show up well on a short intake form. That is one of the clearest signs that a program is taking safety seriously.
Questions to ask before joining any retreat
If you are comparing retreats, ask direct questions in plain language.
- Do you exclude people with psychosis history or a family history of psychosis
- How do you handle bipolar disorder and past mania
- What is your policy for SSRIs, SNRIs, MAOIs and lithium
- Do you review heart conditions and blood pressure history
- Do you require a one-to-one health screening call
- Who makes the final decision on acceptance
Programs that answer these questions clearly are easier to trust. Programs that answer vaguely are giving you useful information too.
Where Jamaica can perform better
Jamaica can make the screening process easier to discuss openly because psilocybin mushrooms were never made illegal there, and Jamaican officials have publicly said it is legal to grow psilocybin mushrooms. That clearer legal footing can let retreats speak more directly about what they screen for and why.
At the same time, legal access should not be confused with formal product approval. Jamaica’s Ministry of Health and Wellness said in August 2024 that it had not approved psilocybin mushroom-containing products for use on the Jamaican market. For a reader comparing destinations, the practical takeaway is that Jamaica may offer clearer retreat logistics, but medical caution still applies and strong intake standards still matter.
Conclusion
We use a one-to-one health call because medication history, past episodes and heart risk need real discussion before a retreat is approved. If you want to review our Negril, Jamaica program, we host retreats through ONE Retreats and you can also see our Google Business Profile and TripAdvisor reviews.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions regarding medical treatments or wellness practices.
